Prevalence and predictors of medication for opioid use disorder among reproductive-aged women

• DOI: 10.1016/j.dadr.2024.100239
• Publication Date: 2024-04-26T16:55:36Z
• Authors: Jennifer K. Bello; Nathaniel A. Dell; Aaron M. Laxton; Mary Conte; Lynn Chen
• Keywords: Odds

Women of reproductive age would benefit from treatment opioid use disorder (OUD) prior to pregnancy improve maternal and infant outcomes. In this study, we aimed identify the prevalence medication for OUD (MOUD) characterize correlates MOUD receipt among 12–49-year-old women with seeking in publicly funded substance programs at time their first episode. This cross-sectional study explores demographic clinical characteristics receiving services. We used data concatenated 2015-2021 Treatment Episode Data Set–Admissions (TEDS-A), which documents patient admissions services United States. sample females aged 12-49 no primary (n=325,512), 40.53% received (n=131,930), including 39.40% non-pregnant (n=115,315) 52.79% pregnant (n=8,423). Pregnant had significantly higher odds (aOR = 2.42, 95%CI: 2.30, 2.54) compared women. Non-white race, setting, self-referral were also associated levels MOUD. identified a significant unmet need both care clinics. While who are more likely receive evidence-based MOUD, still 47.21% did not All reproductive-aged should be offered options,